ZA947739B - Corticoid-17, 21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters processes for their preparation and pharmaceuticals containing these compounds - Google Patents
Corticoid-17, 21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters processes for their preparation and pharmaceuticals containing these compoundsInfo
- Publication number
- ZA947739B ZA947739B ZA947739A ZA947739A ZA947739B ZA 947739 B ZA947739 B ZA 947739B ZA 947739 A ZA947739 A ZA 947739A ZA 947739 A ZA947739 A ZA 947739A ZA 947739 B ZA947739 B ZA 947739B
- Authority
- ZA
- South Africa
- Prior art keywords
- equal
- esters
- corticoid
- corticosteroid
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4333920A DE4333920A1 (de) | 1993-10-05 | 1993-10-05 | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA947739B true ZA947739B (en) | 1995-05-18 |
Family
ID=6499450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA947739A ZA947739B (en) | 1993-10-05 | 1994-10-04 | Corticoid-17, 21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters processes for their preparation and pharmaceuticals containing these compounds |
Country Status (19)
Country | Link |
---|---|
US (1) | US6835724B2 (es) |
EP (1) | EP0646593B1 (es) |
JP (1) | JP3549125B2 (es) |
KR (1) | KR950011463A (es) |
CN (1) | CN1051316C (es) |
AT (1) | ATE210143T1 (es) |
AU (1) | AU679551B2 (es) |
CA (1) | CA2133607C (es) |
DE (2) | DE4333920A1 (es) |
DK (1) | DK0646593T3 (es) |
EC (1) | ECSP941054A (es) |
ES (1) | ES2168283T3 (es) |
FI (1) | FI114158B (es) |
HU (1) | HU219401B (es) |
IL (1) | IL111132A (es) |
NO (1) | NO305483B1 (es) |
PT (1) | PT646593E (es) |
TW (1) | TW283709B (es) |
ZA (1) | ZA947739B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0113042B8 (pt) | 2000-08-05 | 2021-05-25 | Glaxo Group Ltd | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato |
GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
BR0209271A (pt) * | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
US20040248867A1 (en) * | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
KR100472303B1 (ko) * | 2002-05-21 | 2005-03-08 | 김영미 | 결장표적성 프로드럭으로서의 코티코스테로이드21-설페이트 소듐 유도체 |
GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
EP2435462A1 (en) * | 2009-05-29 | 2012-04-04 | Pfizer Limited | Novel glucocorticoid receptor agonists |
CN113092601B (zh) * | 2021-03-02 | 2022-12-20 | 苏州市药品检验检测研究中心 | 一种化妆品中倍他米松17-丙酸酯及倍他米松21-丙酸酯的检测方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133940A (en) * | 1956-04-10 | 1964-05-19 | Glaxo Group Ltd | Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids |
US3201429A (en) * | 1958-07-12 | 1965-08-17 | Syntex Corp | 17, 21-diesters of 6alpha, 16alpha-dimethyl-delta4-pregnen-17alpha-21-diol-3, 20-dione and process therefor |
US3201391A (en) * | 1959-02-18 | 1965-08-17 | Syntex Corp | 6alpha, 9alpha, 11beta-trichloro and 6alpha-fluoro-9alpha, 11beta-dichloro pregnenes |
DE2204366A1 (de) | 1972-01-27 | 1973-08-02 | Dermal Lab Ltd | Steroid-abkoemmlinge |
GB1516095A (en) | 1974-07-31 | 1978-06-28 | Glaxo Lab Ltd | 17,21-diesters of 17alpha,21-dihydroxy-steroids of the pregnane series |
DE2645104C2 (de) | 1976-10-04 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11β-Hydroxy-1,4,8-pregnatrien-3,20-dion-Derivate und Verfahren zu ihrer Herstellung |
DE2735110A1 (de) * | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
DE2817988A1 (de) | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
IL66432A0 (en) * | 1981-08-04 | 1982-12-31 | Plurichemie Anstalt | Process for the preparation of steroidal esters |
EP0095894A3 (en) * | 1982-05-31 | 1985-01-02 | Ohta Seiyaku Kabushiki Kaisha. | 6 alpha-methylprednisolone derivatives |
DE3225848A1 (de) * | 1982-07-07 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Kortikoidhaltige zubereitung zur topischen applikation |
DE3227312A1 (de) * | 1982-07-19 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6,16-dimethylkortikoide, ihre herstellung und verwendung |
DE3243482A1 (de) * | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung |
DE3400188A1 (de) * | 1984-01-02 | 1985-07-11 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Neue 6(alpha),16(alpha)-dimethylkortikoide |
CA1310009C (en) * | 1984-03-28 | 1992-11-10 | John Mark Braughler | Ester prodrugs of steroids |
PT78973A (en) * | 1984-07-25 | 1984-08-01 | Joao Emerico Villax | New preparation process of the 9alpha-fluoro 17,21-acylates or hidroxilades in 17 and 21 chloro-corticosteroid |
DE4025342A1 (de) | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
-
1993
- 1993-10-05 DE DE4333920A patent/DE4333920A1/de not_active Withdrawn
-
1994
- 1994-03-16 EC EC1994001054A patent/ECSP941054A/es unknown
- 1994-04-01 TW TW083102857A patent/TW283709B/zh active
- 1994-09-29 ES ES94115348T patent/ES2168283T3/es not_active Expired - Lifetime
- 1994-09-29 DK DK94115348T patent/DK0646593T3/da active
- 1994-09-29 PT PT94115348T patent/PT646593E/pt unknown
- 1994-09-29 DE DE59409991T patent/DE59409991D1/de not_active Expired - Lifetime
- 1994-09-29 EP EP94115348A patent/EP0646593B1/de not_active Expired - Lifetime
- 1994-09-29 AT AT94115348T patent/ATE210143T1/de active
- 1994-09-30 CN CN94116479A patent/CN1051316C/zh not_active Expired - Fee Related
- 1994-10-03 AU AU74395/94A patent/AU679551B2/en not_active Expired
- 1994-10-03 IL IL11113294A patent/IL111132A/xx not_active IP Right Cessation
- 1994-10-03 HU HU9402831A patent/HU219401B/hu not_active IP Right Cessation
- 1994-10-03 FI FI944599A patent/FI114158B/fi not_active IP Right Cessation
- 1994-10-04 JP JP26323494A patent/JP3549125B2/ja not_active Expired - Lifetime
- 1994-10-04 KR KR1019940025282A patent/KR950011463A/ko not_active Application Discontinuation
- 1994-10-04 NO NO943701A patent/NO305483B1/no not_active IP Right Cessation
- 1994-10-04 ZA ZA947739A patent/ZA947739B/xx unknown
- 1994-10-04 CA CA002133607A patent/CA2133607C/en not_active Expired - Lifetime
-
1997
- 1997-07-22 US US08/897,455 patent/US6835724B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE59409991D1 (de) | 2002-01-17 |
IL111132A0 (en) | 1994-12-29 |
PT646593E (pt) | 2002-05-31 |
DK0646593T3 (da) | 2002-03-18 |
CN1108661A (zh) | 1995-09-20 |
FI114158B (fi) | 2004-08-31 |
HU9402831D0 (en) | 1995-01-30 |
AU679551B2 (en) | 1997-07-03 |
CA2133607A1 (en) | 1995-04-06 |
FI944599A (fi) | 1995-04-06 |
NO943701D0 (no) | 1994-10-04 |
HU219401B (hu) | 2001-04-28 |
ATE210143T1 (de) | 2001-12-15 |
CN1051316C (zh) | 2000-04-12 |
ECSP941054A (es) | 1995-02-27 |
AU7439594A (en) | 1995-04-27 |
EP0646593A1 (de) | 1995-04-05 |
HUT68577A (en) | 1995-06-28 |
JPH07165788A (ja) | 1995-06-27 |
FI944599A0 (fi) | 1994-10-03 |
IL111132A (en) | 2000-10-31 |
NO305483B1 (no) | 1999-06-07 |
JP3549125B2 (ja) | 2004-08-04 |
ES2168283T3 (es) | 2002-06-16 |
EP0646593B1 (de) | 2001-12-05 |
NO943701L (no) | 1995-04-06 |
DE4333920A1 (de) | 1995-04-13 |
US20020103392A1 (en) | 2002-08-01 |
CA2133607C (en) | 2007-07-03 |
US6835724B2 (en) | 2004-12-28 |
KR950011463A (ko) | 1995-05-15 |
TW283709B (es) | 1996-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL111132A (en) | Corticoid-17 21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters processes for their preparation and pharmaceuticals containing these compounds | |
EP0640616A3 (de) | Corticosteroid-17-alkylcarbonat-21-(O)-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel. | |
IL72702A0 (en) | Steroidal carboxylic acid esters,their manufacture and pharmaceutical compositions containing them | |
CA2158610A1 (en) | 17-deoxycorticosteroid-21-/o/-carboxylic esters, processes for their preparation and pharmaceuticals containing these compounds | |
EP0051597B1 (de) | Neue prostacyclinderivate und ihre herstellung | |
EP0350707A1 (de) | Neue Androstan-Derivate |